ENDRA Life Sciences Inc.

NDRANasdaqCM·Healthcare

$4.54▲ +0.32 (+7.58%)

Market openData as of 03:17 PM ET · 15-min delay

Analyst ratingnone

Price target$25.00

Consensus upside+450.7%

Every calculator, already run for NDRA

Open the full toolkit →

What is it worth?

P/E calculatorHow does this multiple compare to peers and its own history?Run →DCF calculatorTen years of free cash flow, discounted back to today.Run →Reverse DCFSolves the price backwards for the growth it already requires.Run →EV / EBITDAThe price with debt added and cash netted off.-0.8x PEG ratioThe multiple divided by the growth meant to justify it.Run →Graham numberGraham's ceiling from earnings and book value.Run →P/S ratioFor companies whose earnings are not the point yet.Run →

You have the numbers on NDRA. Get the argument.

A written report on which of these readings actually decide the outcome for ENDRA Life Sciences Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.

Key market data

Market cap$5.77M

P/E (TTM)—

Forward P/E-1.5x

Beta-0.07

EPS (TTM)$-8.16

Dividend yield—

Volume19.7K

Avg volume31.9K

52-week range

$2.96$9.85

Analyst consensus

1 analysts covering NDRA

Buy1

Hold0

Sell0

Ownership & short interest

Institutions9.7%

Insiders8.7%

Short % float2.3%

Shares out$1.27M

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

HealthcareDiagnostics & Research9 employeesUnited States

NDRA — frequently asked

Is NDRA a buy right now?

Wall Street's consensus rating on ENDRA Life Sciences Inc. is none across 1 analysts, with a mean price target of $25.00 (+451% vs. the current $4.54). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.

Compare ENDRA Life Sciences Inc. against related stocks

Explore additional stock overview pages and jump directly into full report generation for each symbol.

Sector peers

Most-followed names in the same sector.

LLY stock overview UNH stock overview JNJ stock overview MRK stock overview ABBV stock overview PFE stock overview AMGN stock overview ISRG stock overview

Nearby tickers

Additional public equities from our tracked universe.

NDLS stock overview NDAQ stock overview NEE stock overview NCMI stock overview NEM stock overview NCBS stock overview NERI stock overview

Market leaders

Large-cap symbols investors frequently compare.

AAPL stock overview MSFT stock overview NVDA stock overview AMZN stock overview GOOGL stock overview META stock overview TSLA stock overview JPM stock overview

Investor Guides For ENDRA Life Sciences Inc.

Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.

Equity Research ChecklistsThe healthcare diligence checklist worth running before you size anything Earnings Question BanksThe healthcare earnings questions that matter after the headline beat Valuation PlaybooksWhat deserves the multiple in healthcare Red Flag WatchlistsThe healthcare red flags that quietly wreck the thesis

Generate your full NDRA research report

DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ENDRA Life Sciences Inc., in minutes. 3 free reports included with every account — no credit card required.